Galapagos Nv (GLPG) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Galapagos Nv  (NASDAQ: GLPG)


Galapagos Nv's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Galapagos Nv's ROI in the fourth quarter of 2025?
Galapagos Nv achieved a return on average invested assets (ROI) of 9.76 % in its fourth quarter of 2025, this is above GLPG's average return on investment of -0.73%.
Galapagos Nvs investments during the 12 months ending in the fourth quarter of 2025 are valued at $3 billion

ROI has improved compared to 2.22% in the third quarter of 2025, due to net income growth.

Within the Healthcare sector 125 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from 0 to 854.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM -12.18 % -12.89 % -10.03 % -7.23 % -4.47 %
Y / Y Net Income Change TTM 333.15 % -65.01 % -65.01 % -65.01 % -65.01 %
Investment (TTM) in Millions 3,821 3,638 3,638 3,638 4,009
Return On Investment (TTM) 9.76 % 2.22 % 2.14 % 2.05 % 1.98 %
GLPG's Overall Ranking # 854 # 0 # # #
Seq. Investment Change TTM -1.26 % -3.98 % -3.83 % -3.69 % -2.06 %
Seq. Net Income Change TTM 333.15 % 0 % 0 % 0 % -65.01 %
Net Income (TTM) in Millions 359 83 83 83 83

GLPG Company Profile >> Back to GLPG Roi Comparisons >> See Annual GLPG Return On Investment



Return On Investment GLPG's Ranking
Within: No.
Industry # 54
Sector # 126
Overall # 854

Return On Investment Statistics
High Average Low
9.88 %
-0.73 %
-9 %
(Dec 31 2025)   (Dec 31 2017)







Financial Statements
Galapagos Nv's IV. Quarter Investments $ 3,821 Millions GLPG's Balance sheet
Galapagos Nv's IV. Quarter Income $ 359 Millions Quarterly GLPG's Income Statement
GLPG's Income by Division See GLPG's Income by Division


GLPG Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 3,812 4,009 4,362 4,589 5,213
Y / Y Investment Growth -4.92 % -8.09 % -4.96 % -11.96 % -12.64 %
Net Income in Millions 363 80 229 -230 -122
Y / Y Net Income Growth 352.61 % -64.99 % - - -
Annual Return On Investment 9.52 % 2 % 5.25 % -5 % -2.34 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 9.52 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
GLPG's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for GLPG's Competitors
Subscribers only: Roi for Galapagos Nv's Suppliers
Subscribers only: Return On Investment for GLPG's Customers

Other Ratios
GLPG's Roa GLPG's Inventory Turnover Ratio GLPG's Growth Rates GLPG's Dividend Statistics
GLPG's Profitability Ratios GLPG's Asset Turnover Ratio GLPG's Dividend Growth
GLPG's Roe GLPG's Valuation Ratios GLPG's Financial Strength Ratios GLPG's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Vaxart Inc   26.63 %
Compugen Ltd  26.32 %
Arrowhead Pharmaceuticals Inc   25.56 %
Puma Biotechnology Inc   25.39 %
Catalyst Pharmaceuticals Inc   24.25 %
Iradimed Corporation  22.97 %
Innoviva Inc   22.62 %
Illumina Inc   22.37 %
Transmedics Group Inc   21.99 %
Zoetis Inc   21.25 %
Pro dex Inc   21.04 %
Dexcom Inc   20.78 %
Electromed Inc   20.50 %
Resmed Inc   20.35 %
Merck and Co Inc   20.17 %
Astrazeneca Plc  19.67 %
Vertex Pharmaceuticals Inc  19.48 %
Inspire Medical Systems inc   19.34 %
Mimedx Group Inc   19.27 %
Gilead Sciences Inc   19.26 %
United Therapeutics Corporation  18.71 %
Krystal Biotech Inc   18.51 %
Agilent Technologies inc   18.50 %
Chemed Corporation  18.05 %
Hca Healthcare Inc   17.95 %
Sbc Medical Group Holdings Incorporated  17.85 %
Lifevantage Corp  17.77 %
Embecta Corp   17.69 %
Waters Corporation  17.39 %
Spero Therapeutics Inc   16.92 %

Date modified: 2026-07-07T11:24:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.